Mehlis Katja, Bierwirth Elena, Laryionava Katsiaryna, Mumm Friederike, Heussner Pia, Winkler Eva C
Medical Oncology, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Institut für physikalische und rehabilitative Medizin, Klinikum Ingolstadt GmbH, Ingolstadt, Germany.
ESMO Open. 2020 Oct;5(5):e000950. doi: 10.1136/esmoopen-2020-000950.
Decisions to limit treatment (DLTs) are important to protect patients from overtreatment but constitute one of the most ethically challenging situations in oncology practice. In the Ethics Policy for Advance Care Planning and Limiting Treatment study (EPAL), we examined how often DLT preceded a patient's death and how early they were determined before (T1) and after (T2) the implementation of an intrainstitutional ethics policy on DLT.
This prospective quantitative study recruited 1.134 patients with haematological/oncological neoplasia in a period of 2×6 months at the University Hospital of Munich, Germany. Information on admissions, discharges, diagnosis, age, DLT, date and place of death, and time span between the initial determination of a DLT and the death of a patient was recorded using a standardised form.
Overall, for 21% (n=236) of the 1.134 patients, a DLT was made. After implementation of the policy, the proportion decreased (26% T1/16% T2). However, the decisions were more comprehensive, including more often the combination of 'Do not resuscitate' and 'no intense care unit' (44% T1/64% T2). The median time between the determination of a DLT and the patient's death was similarly short with 6 days at a regular ward (each T1/T2) and 10.5/9 (T1/T2) days at a palliative care unit. For patients with solid tumours, the DLTs were made earlier at both regular and palliative care units than for the deceased with haematological neoplasia.
Our results show that an ethics policy on DLT could sensitise for treatment limitations in terms of frequency and extension but had no significant impact on timing of DLT. Since patients with haematological malignancies tend to undergo intensive therapy more often during their last days than patients with solid tumours, special attention needs to be paid to this group. To support timely discussions, we recommend the concept of advance care planning.
限制治疗的决策(DLTs)对于保护患者避免过度治疗很重要,但却是肿瘤学实践中最具伦理挑战性的情况之一。在《预先护理计划与限制治疗伦理政策》研究(EPAL)中,我们研究了限制治疗决策在患者死亡之前出现的频率,以及在机构内部实施关于限制治疗决策的伦理政策之前(T1)和之后(T2),这些决策被确定的时间有多早。
这项前瞻性定量研究在德国慕尼黑大学医院,分两个6个月的时间段招募了1134例血液学/肿瘤学肿瘤患者。使用标准化表格记录入院、出院、诊断、年龄、限制治疗决策、死亡日期和地点,以及从首次确定限制治疗决策到患者死亡的时间跨度。
总体而言,在1134例患者中,有21%(n = 236)做出了限制治疗决策。政策实施后,这一比例有所下降(T1时为26%/T2时为16%)。然而,这些决策更加全面,更多地包括了“不进行心肺复苏”和“不进入重症监护病房”的组合(T1时为44%/T2时为64%)。确定限制治疗决策与患者死亡之间的中位时间同样较短,在普通病房为6天(T1和T2时均如此),在姑息治疗病房为10.5/9天(T1/T2)。对于实体瘤患者,在普通病房和姑息治疗病房做出限制治疗决策的时间都比血液学肿瘤患者更早。
我们的结果表明,关于限制治疗决策的伦理政策在频率和范围方面可能会提高对治疗限制的敏感性,但对限制治疗决策的时间没有显著影响。由于血液系统恶性肿瘤患者在生命的最后几天比实体瘤患者更常接受强化治疗,因此需要特别关注这一群体。为了支持及时进行讨论,我们推荐预先护理计划的理念。